- US-listed companies
- Ultragenyx Pharmaceutical Inc.
- Income statement
Ultragenyx Pharmaceutical Inc.RARE
Market cap
$3.2B
P/E ratio
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | - | - | 0 | 3 | 51 | 104 | 271 | 351 | 363 | 434 | 560 |
| Revenue growth (%) | - | - | - | ||||||||
| Cost of revenue | - | - | - | 0 | 1 | - | - | - | - | - | - |
| Research & development | 46 | 115 | 183 | 232 | 294 | 357 | 412 | 497 | 706 | 648 | 698 |
| Selling, general & administrative | - | - | - | 100 | 128 | 162 | 183 | 220 | 278 | 310 | 322 |
| Operating margin (%) | - | - | |||||||||
| Operating income | -57 | -148 | -248 | -329 | -371 | -424 | -330 | -382 | -649 | -569 | -536 |
| Operating expenses | 57 | 148 | 248 | 332 | 423 | 528 | 601 | - | - | - | - |
| Income before tax | - | - | -246 | -318 | -197 | -399 | -185 | -453 | -702 | -608 | -568 |
| Pretax margin (%) | - | - | -184,841.4 | -12,187.5 | -382.7 | -385.1 | -68.4 | -128.9 | -193.1 | -140.1 | -101.3 |
| Provision for income taxes | - | - | 0 | -16 | 1 | 3 | 1 | 1 | 6 | -2 | 2 |
| Effective tax rate (%) | - | - | |||||||||
| Net income | -60 | -146 | -246 | -302 | -198 | -403 | -187 | -454 | -707 | -607 | -569 |
| Net income margin (%) | - | - | |||||||||
| Earnings per share | - | - | - | - | - | - | - | - | -10.12 | -8.25 | -6.29 |
| Diluted EPS | - | - | - | - | - | - | - | - | -10.12 | -8.25 | -6.29 |
| Dividend per share | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | |||||||||||
| EBITDA margin (%) | - | - |